Pioneering the Future of Cancer Treatment: Samsung Bioepis Accelerates Development of Keytruda Biosimilar
In the high-stakes world of biopharmaceuticals, Samsung Bioepis is setting the pace by intensifying its development efforts for a biosimilar of Keytruda, Merck’s (MSD) leading immunotherapy drug. This comes at a crucial time as the global market for such therapies is projected to reach a staggering KRW 72 trillion. Samsung Bioepis has recently announced the … 더 읽기